about
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjectsImmunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculusNonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation?Resolution of inflammation in periodontitisParadigm shift in the pharmacological management of periodontal diseases.Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Cyclooxygenase-2 inhibitors: promise or peril?
@ast
Cyclooxygenase-2 inhibitors: promise or peril?
@en
type
label
Cyclooxygenase-2 inhibitors: promise or peril?
@ast
Cyclooxygenase-2 inhibitors: promise or peril?
@en
prefLabel
Cyclooxygenase-2 inhibitors: promise or peril?
@ast
Cyclooxygenase-2 inhibitors: promise or peril?
@en
P2860
P921
P1476
Cyclooxygenase-2 inhibitors: promise or peril?
@en
P2093
Benjamin D Schwartz
Laurel J Mengle-Gaw
P2860
P304
P356
10.1080/09629350290000041
P577
2002-10-01T00:00:00Z